About Kite Pharma
Kite Pharma is a company based in Los Angeles (United States) founded in 2009 was acquired by Gilead in August 2017. It operates as a HealthTech. Kite Pharma has raised $97.7 million across 7 funding rounds from investors including Gilead, Amgen Business Development and Alta Partners. The company has 17 employees as of December 31, 2022. Kite Pharma has completed 4 acquisitions, including Cell Design Labs, Gadeta and Interius Biotherapeutics. Kite Pharma offers products and services including Yescarta and CAR T-Cell Therapy. Kite Pharma operates in a competitive market with competitors including Senti Biosciences, Caribou Biosciences, Poseida Therapeutics, Immunocore and Juno Therapeutics, among others.
- Headquarter Los Angeles, United States
- Employees 17 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Gilead Sciences, Inc.
-
Annual Revenue
$294 M-66as on Dec 31, 2024
-
Net Profit
$480 M-92as on Dec 31, 2024
-
EBITDA
$1.66 B-78as on Dec 31, 2024
-
Total Equity Funding
$97.7 M (USD)
in 7 rounds
-
Latest Funding Round
$300 M (USD), Post-IPO
Apr 03, 2018
-
Investors
Gilead
& 5 more
-
Employee Count
17
as on Dec 31, 2022
-
Investments & Acquisitions
Cell Design Labs
& 3 more
-
Acquired by
Gilead
(Aug 25, 2017)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Kite Pharma
Kite Pharma offers a comprehensive portfolio of products and services, including Yescarta and CAR T-Cell Therapy. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Yescarta is used for treating blood cancer effectively.
Custom therapy is developed for blood cancer treatment.
Unlock access to complete
Unlock access to complete
Leadership Team
294 people
Software Development Team
183 people
Senior Team
62 people
Legal and Compliance
41 people
Data Analysis and Operations Team
38 people
Human Resources and Administration
38 people
Operations Team
38 people
Finance and Accounting
36 people
Unlock access to complete
Funding Insights of Kite Pharma
Kite Pharma has successfully raised a total of $97.7M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $300 million completed in April 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 7
- Last Round Post-IPO — $300.0M
-
First Round
First Round
(09 Mar 2011)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2018 | Amount | Post-IPO - Kite Pharma | Valuation |
investors |
|
| Jan, 2015 | Amount | Post-IPO - Kite Pharma | Valuation |
investors |
|
| Dec, 2014 | Amount | Post-IPO - Kite Pharma | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Kite Pharma
Kite Pharma has secured backing from 6 investors, including venture fund, angel, and institutional investors. Prominent investors backing the company include Gilead, Amgen Business Development and Alta Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are facilitated by Amgen-backed entity.
|
Founded Year | Domain | Location | |
|
Venture capital firm focused on healthcare companies
|
Founded Year | Domain | Location | |
|
Pontifax Venture Capital is focused on life sciences investments.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Kite Pharma
Kite Pharma has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include Cell Design Labs, Gadeta and Interius Biotherapeutics. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Developer of gene therapies for treating multiple diseases
|
2020 | ||||
|
CAR T-cell immunotherapies for cancer and diseases are developed.
|
2016 | ||||
|
T Cell based cancer therapies based on gamma delta (γδ) T cell receptors
|
2015 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Kite Pharma
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Kite Pharma Comparisons
Competitors of Kite Pharma
Kite Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Senti Biosciences, Caribou Biosciences, Poseida Therapeutics, Immunocore and Juno Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Cell-based therapies for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Provider of cell therapies to treat cancer and hematologic conditions
|
|
| domain | founded_year | HQ Location |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| domain | founded_year | HQ Location |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer
|
|
| domain | founded_year | HQ Location |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| domain | founded_year | HQ Location |
T cell-based treatments for immunological and oncological disorders are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Kite Pharma
Frequently Asked Questions about Kite Pharma
When was Kite Pharma founded?
Kite Pharma was founded in 2009 and raised its 1st funding round 2 years after it was founded.
Where is Kite Pharma located?
Kite Pharma is headquartered in Los Angeles, United States. It is registered at Los Angeles, California, United States.
Is Kite Pharma a funded company?
Kite Pharma is a funded company, having raised a total of $97.7M across 7 funding rounds to date. The company's 1st funding round was a Post-IPO of $188M, raised on Mar 09, 2011.
How many employees does Kite Pharma have?
As of Dec 31, 2022, the latest employee count at Kite Pharma is 17.
What is the annual revenue of Kite Pharma?
Annual revenue of Kite Pharma is $294M as on Dec 31, 2024.
What does Kite Pharma do?
Kite Pharma is dedicated to advancing cell therapy solutions for cancer treatment. The company specializes in CAR T-cell therapy, a personalized treatment designed to harness the immune system against blood cancers. Research and development efforts are directed toward improving patient responses, exploring diverse therapy modalities, and enhancing manufacturing speed. Operations are centered in the healthcare and biotechnology sector with a mission to achieve cures for cancer.
Who are the top competitors of Kite Pharma?
Kite Pharma's top competitors include Immunocore, Juno Therapeutics and Lyell Immunopharma.
What products or services does Kite Pharma offer?
Kite Pharma offers Yescarta and CAR T-Cell Therapy.
How many acquisitions has Kite Pharma made?
Kite Pharma has made 4 acquisitions, including Cell Design Labs, Gadeta, and Interius Biotherapeutics.
Who are Kite Pharma's investors?
Kite Pharma has 6 investors. Key investors include Gilead, Amgen Business Development, Alta Partners, Pontifax Venture Capital, and Arie Belldegrun.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.